FDA Approves Lumipulse Blood Test to Aid Alzheimer’s Diagnosis

Champaign Urbana & Springfield Decatur, IL, October 16, 2026 —

The U.S. Food and Drug Administration has approved Lumipulse, described as the first blood test designed to aid in diagnosing Alzheimer’s disease. The test is intended to offer an alternative to established diagnostic methods, including PET scans and spinal taps.

Compared with those methods, Lumipulse is described as less invasive and potentially faster, as well as more accessible. The development is intended to support earlier detection of the disease and improve access to treatment. The summary provided does not specify how the test is used in clinical practice or what role its results play in a diagnosis.

The approval marks the introduction of a blood-based option for aiding Alzheimer’s diagnosis, but details about the decision and the test’s use were not provided. The date of the FDA approval, the company that makes Lumipulse and the patient population for whom it is intended were not specified. No information was provided about the test’s accuracy, limitations, cost, or availability.

The summary also does not describe whether Lumipulse is intended to replace or complement PET scans and spinal taps, or what other evaluations may be used alongside it. While the test is presented as a potentially faster and more accessible alternative, no timelines or comparative data were included. The FDA’s approval is reported, but the specific conditions attached to that approval were not provided.

For now, the stated significance of Lumipulse is its potential to make an aid to Alzheimer’s diagnosis less invasive and more accessible. Further details about how the test will be offered and incorporated into diagnostic care were not included in the information available.

Story summarized from the original created by Heather Graf on www.wandtv.com, see more information here.

Media gallery